Business Wire

Aqara Adds Presence Sensor FP2 to its Smart Sensor Portfolio

20.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Aqara, a leading provider of smart home products, expands its wide-ranged smart sensor portfolio with the introduction of the Presence Sensor FP2, a revolutionary sensor for precise human presence detection. Equipped with the millimeter wave (mmWave) radar technology, the FP2 solves many pain points of the traditional passive infrared (PIR) presence sensors and enables a more tailored and rich smart home experience. The new sensor is now available on the Company’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as selective Aqara retailers worldwide1.

Accurate human presence detection provides essential information for tailored smart home automations such as home security monitoring and energy management systems (e.g., automated lights, HVAC, home appliances control). The mmWave-based FP2 Presence Sensor takes a leap forward from the PIR motion sensors as the former detects a person’s presence with even the slightest movement such as the act of breathing. Gone are the frustrating experiences of having your smart lights turn off unintentionally because you were sitting still reading a book or working at the desk.

Moreover, the FP2 sensor raises the precision of human detection to the next level with its capability to monitor multiple zones and multiple targets simultaneously. The FP2 allows the user to define up to 30 zones within a room (up to 40 sq m/430 sq ft). For example, the living room and dining area can be configured as separate zones with individualized automations. This sensor tracks up to 5 persons at the same time2, making it possible to control different zones based on the real-time location of each family member. For instance, to dim the dining area lights and switch the TV on when the kids leave the dining table and move to the sofa, meanwhile to keep the kitchen light on when someone is washing the dishes.

The powerful capabilities of the FP2 sensor can also be used within the third-party smart home platforms including Apple Home, Amazon Alexa, Google Home, Home Assistant3 and more. Once the zones are set up in the Aqara Home app, the zone configuration can be synced to these platforms as multiple motion/occupancy sensors, allowing users to trigger zone-based automation with a wide variety of third-party smart home devices. Support of the new smart home standard, Matter, is also planned for the FP2, and will be added to the device via a subsequent OTA update4.

Aside from its precise presence detection and multi-zone automations, FP2 also has fall detection built-in5, which is particularly essential for senior citizens who are more vulnerable to fall injuries. Families and caregivers can be alerted by both local siren and remote alerts if the FP2 sensor detects a fall, which allows them to seek immediate assistance if necessary. The FP2 sensor can detect a fall at the home in a convenient way without the need to wear additional devices on the body. At the same time, unlike a typical security camera, the Sensor provides meaningful alerts and data without intruding on a person’s personal privacy.

Thanks to its powerful hardware, the FP2 sensor will be able to support much more cutting-edge features in the future such as posture detection, which not only recognizes falls but also other postures including standing, sitting, and lying. Sleep monitoring and respiratory rate detection capabilities could also be achieved via the FP2 in the future. These advanced features will be added to the FP2 sensor via future OTA updates4.

For more details of the Presence Sensor FP2, please visit our website.

  1. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real-time availability.
  2. The best result can be achieved in the case of tracking not more than 3 persons.
  3. The FP2 sensor can be added to Home Assistant using HomeKit Controller integration.
  4. Some features of the FP2 sensor such as Matter support, posture detection and sleep monitor are not available by the time of launch.
  5. The Presence Sensor FP2 is not a medical device, and can only be used for notification purposes. Ceiling-mounted installation is required for fall detection, and the monitoring area will decrease when the FP2 is ceiling-mounted. In fall detection mode, many functionalities of the FP2 become unavailable, including zone positioning and multi-person detection.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Inquiry:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye